title: Personalized immunotherapy for the treatment of non-Hodgkin's lymphoma: a promising approach.
abstract: The efficacy of immunotherapeutic strategies for the treatment of lymphoid malignancies has been demonstrated in recent years. In patients with B-cell lymphomas, particularly indolent lymphoma, the use of passive immunotherapy, such as the anti-CD20 monoclonal antibody rituximab, has made an impressive impact on patient outcome. Personalized immunotherapy, a method that triggers the immune system to mount a response against tumor cells, has shown promising results in early clinical trials in hematologic malignancies. This therapeutic modality appears safe, with the most common adverse events being transient, local reactions at the site of injection. Furthermore, personalized immunotherapy has the potential to generate immunologic memory, which could provide prolonged remission. Currently, 3 large phase III studies are evaluating the efficacy and safety of personalized immunotherapy in patients with follicular lymphoma. It is hoped that the results of these studies will lead to the incorporation of this promising approach into the standard treatment of patients with lymphoma.
authors.affiliation: Section of Oncology/Hematology, University of Nebraska Medical Center, Omaha, NE 681980-7680, USA. jmvose@unmc.edu
authors.forename: Julie M
authors.initials: JM
authors.lastname: Vose
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D019496:Cancer Vaccines; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D006689:Hodgkin Disease / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*
chemical_list: D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D016178:Granulocyte-Macrophage Colony-Stimulating Factor